Healthcare
PureTech Health plc(PRTC)
Live Price
Offline$17.31
+2.64% today
Window Change
-6.96%
Window
May 26, 2026 โ Jun 12, 2026
- Market Cap
- $440.00M
- Revenue Growth
- -3.5%
- EPS Growth
- -2400.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 14 bars ยท May 26, 2026 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PureTech Health plc (PRTC) is a Healthcare stock with a market cap of $440.00M and listed on NASDAQ. The stock last traded around $17.31 and down 7.0% across the available one-year price window (May 26, 2026 โ Jun 12, 2026). Baseline metrics include revenue growth of -3.5%, EPS growth of -2400.0%, a dividend yield of 0.0%. What stands out right now is revenue -3.5%, EPS -2400.0%, free cash flow +36.5% with operating margin -2115.4% and ROIC -19.6%. Valuation already assumes a fairly strong business story at price/sales 95.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRTC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.5% vs +7.6% peer median
Operating Margin
Below sector median
-2115.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -3.5% and EPS is at -2400.0%, with operating margin around -2115.4%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRTC
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRTC Max Drawdown
-10.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRTC and SPY.
Company Overview
PureTech Health plc
NASDAQ Global Market
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Leadership
- Robert Lyne
- IPO Date
- Nov 16, 2020
- Employees
- 80
- Street Address
- 6 Tide Street
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 482 2333
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 95.0
- Price/Book
- 0.1
Growth
- Revenue
- -3.5%
- EPS
- -2400.0%
- Free Cash Flow
- +36.5%
Profitability
- Gross Margin
- -471.2%
- Operating Margin
- -2115.4%
- Net Margin
- -2355.5%
- ROE
- -31.8%
- ROIC
- -19.6%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 6.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.